# Calceolarioside A

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/calceolarioside-a
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-20
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Calceolarioside A, Phenylpropanoid glycoside from Calceolaria, Fraxinus insularis glycoside, Aeschynanthus bracteatus compound, CALC-A, Calceolaria phenylpropanoid

## Overview

Calceolarioside A is an iridoid glycoside compound that demonstrates significant antinociceptive and anti-inflammatory properties through modulation of pain and [inflammatory pathway](/ingredients/condition/inflammation)s. Research shows it reduces pain responses by up to 75% and alleviates thermal hyperalgesia in preclinical studies.

## Health Benefits

• Reduces formalin-induced licking by 35% in phase 1 and 75% in phase 2 in mice, indicating antinociceptive properties (preclinical evidence).[3] • Alleviates carrageenan-induced thermal hyperalgesia in mice at 50-100 μg/paw dosage (preclinical evidence).[3] • Diminishes zymosan-induced paw edema in mice by reducing edema 1-4 hours post-administration with 50-100 μg/paw (preclinical evidence).[3] • Inhibits IL-6, TNFα, and IL-1β release from LPS-stimulated THP-1 cells in a concentration-dependent manner, showcasing [anti-inflammatory](/ingredients/condition/inflammation) effects (in vitro evidence).[3]

## Mechanism of Action

Calceolarioside A exerts its antinociceptive effects by modulating nociceptive pathways involved in pain transmission, particularly targeting formalin-induced pain responses. The compound demonstrates [anti-inflammatory](/ingredients/condition/inflammation) activity by inhibiting inflammatory mediators that contribute to carrageenan-induced thermal hyperalgesia and zymosan-induced edema formation.

## Clinical Summary

Current evidence for calceolarioside A is limited to preclinical animal studies with no human clinical trials available. Mouse studies demonstrate significant antinociceptive effects, showing 35% reduction in phase 1 and 75% reduction in phase 2 formalin-induced licking responses. Additional research shows effectiveness against thermal hyperalgesia at 50-100 μg/paw dosages and reduction of paw edema in [inflammation](/ingredients/condition/inflammation) models. The evidence strength remains preliminary due to the absence of human studies.

## Nutritional Profile

Calceolarioside A is a phenylpropanoid glycoside (phenylethanoid glycoside) compound, not a food ingredient or macronutrient source. It contains no meaningful macronutrients (protein, fat, or carbohydrates in a nutritional sense), fiber, or conventional vitamins/minerals. Structurally, it is composed of a caffeic acid ester linked to a glycoside backbone, contributing to its classification as a polyphenolic bioactive compound. Molecular formula: C20H22O11 (approximate molecular weight ~442 g/mol). Its bioactive profile is defined by its catechol moiety and caffeic acid component, which confer [antioxidant](/ingredients/condition/antioxidant) and [anti-inflammatory](/ingredients/condition/inflammation) properties. Bioavailability data in humans is not established; preclinical studies utilized direct intraplantar administration (50–100 μg/paw in mice), bypassing oral absorption. Oral bioavailability of phenylethanoid glycosides as a class is generally limited due to hydrolysis by gut microbiota and intestinal enzymes, which may cleave the glycoside linkage and alter bioactivity. No data exists on standard nutritional concentrations, dietary intake levels, or micronutrient contributions, as this compound is studied exclusively as an isolated phytochemical in pharmacological contexts rather than as a dietary nutrient.

## Dosage & Preparation

No clinically studied dosage ranges exist due to the lack of human trials. In preclinical studies, doses of 50-100 μg/paw were used for anti-hyperalgesic and anti-edema effects in mice. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

No human safety data exists for calceolarioside A due to lack of clinical trials. Potential interactions with pain medications, NSAIDs, or [anti-inflammatory](/ingredients/condition/inflammation) drugs are unknown but theoretically possible given its mechanism of action. Pregnancy and breastfeeding safety cannot be established without human studies. Long-term safety, optimal dosing, and contraindications remain undefined pending clinical research.

## Scientific Research

No human clinical trials or meta-analyses have been conducted on Calceolarioside A. The existing evidence is limited to in vitro studies and animal models, such as those involving paw injection in mice demonstrating antinociceptive and [anti-inflammatory](/ingredients/condition/inflammation) effects (PMID: 35408584).[3]

## Historical & Cultural Context

There are no documented traditional or historical medicinal uses for Calceolarioside A. It is primarily studied as a phytochemical isolate without noted ethnopharmacological context.

## Synergistic Combinations

Acteoside, Forsythiaside, Verbascoside

## Frequently Asked Questions

### How much pain relief does calceolarioside A provide?

Studies show calceolarioside A reduces formalin-induced pain responses by 35% in acute phase and 75% in inflammatory phase. It also effectively alleviates thermal hyperalgesia at doses of 50-100 μg/paw in animal models.

### What type of compound is calceolarioside A?

Calceolarioside A is an iridoid glycoside, a class of naturally occurring compounds known for their biological activity. Iridoid glycosides are characterized by their cyclopentane ring structure and sugar moiety.

### Has calceolarioside A been tested in humans?

No human clinical trials have been conducted with calceolarioside A. All current evidence comes from preclinical mouse studies examining pain and inflammation responses.

### Can calceolarioside A reduce inflammation?

Yes, research demonstrates calceolarioside A reduces zymosan-induced paw edema in mice and alleviates carrageenan-induced thermal hyperalgesia. These effects suggest significant anti-inflammatory properties in preclinical models.

### What conditions might calceolarioside A help with?

Based on preclinical evidence, calceolarioside A may potentially help with pain conditions and inflammatory disorders. However, human efficacy remains unproven without clinical trials to establish therapeutic applications.

### What does the research evidence show about calceolarioside A's effectiveness?

Current evidence for calceolarioside A comes exclusively from preclinical animal studies in mice, showing antinociceptive (pain-blocking) effects in formalin and thermal hyperalgesia models, and anti-inflammatory effects in edema models. No human clinical trials have been conducted to date, meaning efficacy and safety in people remain unestablished. The preclinical data is promising but represents early-stage research that requires further development before human use can be recommended.

### Who should avoid calceolarioside A supplementation?

Because calceolarioside A has not been studied in humans, it should be avoided by pregnant women, nursing mothers, and children until safety data becomes available. Individuals with allergies to Calceolaria species plants should also exercise caution, as cross-reactivity is possible. Anyone taking pain management or anti-inflammatory medications should consult a healthcare provider before use, as potential interactions are unknown.

### What is the optimal dosage of calceolarioside A based on available research?

In preclinical mouse studies, calceolarioside A was effective at doses of 50-100 μg/paw for reducing inflammation and pain responses, but this translates to injected paw administration rather than oral supplementation. No oral dosing studies or human dosage recommendations exist for calceolarioside A. Until human clinical trials establish safe and effective doses, no specific supplementation dosage can be recommended.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*